The role of the blood-brain barrier in the aetiology of permanent brain dysfunction in hyperphenylalaninaemia
- 31 Downloads
Calculations on the rate of entry of the neutral amino acids into the brain via the blood-brain barrier show that a considerable decrease in this rate, particularly for tryptophan and tyrosine, takes place in histidinaemia and tyrosinaemia, type II. These conditions are, however, not associated with mental retardation. It is therefore concluded that effects at the blood-brain barrier alone do not provide an adequate explanation for the aetiology of permanent brain dysfunction in hyperphenylalaninaemia.
Unable to display preview. Download preview PDF.
- Baños, G., Daniel, P. M., Moorhouse, S. R. and Pratt, O. E. Inhibition of entry of some amino acids into the brain with observations on mental retardation in the amino acidurias.Psychol. Med. 4 (1977) 262–270Google Scholar
- Berger, R., Springer, J. and Hommes, F. A. Brain protein and myelin metabolism in young hyperphenylalaninemic rats.Mol. Cell Biol. 26 (1980) 31–36Google Scholar
- Buist, N. R. M., Kennaway, N. G. and Fellman, J. H. Tyrosinemia type II: hepatic cytsol tyrosine aminotransferase deficiency (The ‘Richner-Hahnart Syndrome’). In Bickel, H. and Wachtel, U. (eds)Inherited Diseases of Amino Acid Metabolism. Recent Progress in the Understanding, Recognition and Management, Thieme Verlag, Stuttgart, 1985, pp. 203–235Google Scholar
- Curtius, H. Ch., Niederwieser, A., Viscontini, M., Leimbacher, W., Wegman, H., Biehova, B., Rey, F., Schaub, J. and Schmidt, H. Serotonin and dopamine synthesis in phenylketonuria.Exp. Med. Biol. 133 (1981) 277–291Google Scholar
- Elsas, L. J. and Trotter, J. F. Changes in physiological concentrations of blood phenylalanine produce sensitive parameters of human brain function. In Wurtman, R. J. and Rittar-Walker, E. (eds)Dietary Phenylalanine and Brain Function, Birkhäuser, Boston, 1988, pp. 187–195Google Scholar
- La Du, B. N. Histidinemia. In Stanbury, J. B., Wyngaarden, J. B. and Frederickson, D. S. (eds)The Metabolic Basis of Inherited Disease, McGraw-Hill, New York, 1978, pp. 317–327Google Scholar
- Linneweh, F. and Ehrlich, M. Zur pathogenase des Schwachsinns bei Phenylketonurie.Klin. Wschr. 40 (1960) 225–226Google Scholar
- Lou, H. C. Large doses of tryptophan and tyorsine as potential therapeutic alternative to dietary phenylalanine restriction in phenylketonuria.Lancet 2 (1985) 150–151Google Scholar
- Pardridge, W. M. Phenylalanine transport at the human blood-brain barrier. In Wurtman, R. J. and Ritter-Walker, E. (eds)Dietary Phenylalanine and Brain Function, Birkhäuser, Boston, 1988, pp. 55–62Google Scholar
- Pratt, O. E. A new approach to the treatment of phenylketonuria.J. Ment. Def. Res. 24 (1980) 203–217Google Scholar
- Pratt, O. E. The need of the brain for amino acids and how they are transported across the blood-brain barrier. In Belton, N. R. and Toothill, C. (eds)Transport and Inherited Disease, MTP Press, Boston, 1981, pp. 87–122Google Scholar
- Tada, K., Tateda, H., Arishima, S., Soksi, K., Kitagawa, T., Aoki, K., Suwa, S., Kawamura, M., Oura, T., Takesada, M., Kuroda, Y., Yamashita, F., Matsuda, I. and Naruse, H. Follow-up of a nationwide screening for inborn errors of metabolism in Japan.Eur. J. Pediatr. 142 (1984) 204–207PubMedGoogle Scholar